Navigation Links
Preoperative breast MRI suggests high cancer yield

The use of preoperative Breast MRI detects otherwise occult cancer with a relatively high degree of accuracy when applied to a diverse population of patients newly diagnosed with breast cancer, according to a study in the January issue of the American Journal of Roentgenology.

The study was performed at the University of Washington and Seattle Cancer Care Alliance in Seattle, WA.

The review initiated with 592 patients who were recently diagnosed with breast cancer and underwent staging with preoperative breast MRI. The analysis set was comprised of 570 patients, whose biopsy rates, positive predictive values (PPVs) of biopsy, and overall cancer yields were calculated and compared using the chi-square test across patient age, breast density, index tumor type, receptor status and lymph node status.

"Our data add to the growing body of literature that documents breast MRI's ability to detect otherwise occult additional disease in patients who have been newly diagnosed with breast cancer," said Robert Gutierrez, MD, lead author of the study.

"We found that use of preoperative breast MRI in newly diagnosed cancer patients resulted in an added cancer yield of 12%.This is much higher than the added cancer yield of .08 to 6.7% seen with high risk screening breast MRI, a more widely accepted indication for breast MRI, " said Gutierrez.

"A major strength of our study is our sample size of 570 patients, which is larger than most prior investigations. Additionally, unlike the majority of preoperative breast MRI studies, our patient population is more representative of a broad diagnostic population, which is a result of the practice pattern at our site of routinely performing preoperative breast MRI in newly diagnosed breast cancer patients, "he said.

This study appears in the January 2011 issue of the American Journal of Roentgenology.


Contact: Keri Sperry
American College of Radiology / American Roentgen Ray Society

Page: 1

Related medicine news :

1. Preoperative/neoadjuvant therapy in pancreatic cancer
2. Preoperative MRI assists in surgical planning and helps spare erectile function after RALP
3. Can eGFR be a routine preoperative renal function test?
4. Response to preoperative therapy may predict survival in pancreatic cancer patients
5. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
6. Low forms of cyclin E reduce breast cancer drugs effectiveness
7. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
8. For Some Breast Cancer Patients, Shorter Radiation Works Well
9. Short-term radiation therapy successful on breast cancer
10. Few Women at High Risk for Breast Cancer Take Tamoxifen
11. Hormone May Prevent Aggressive Breast Cancer
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: